This third booklet of the World Drug Report 2022 has a dual focus: opioids and cannabis.
The first chapter of the booklet provides an overview of opioids as a group of substances and their patterns of non-medical use at the global level. It also reviews the latest trends in the global supply of opi...ates and synthetic opioids and the availability of pharmaceutical opioids for medical consumption. Issues specific to regional patterns and trends in opioid markets are also analysed, including the opioid crisis in North America and in Africa and the Middle East. The chapter also includes a discussion of the potential impact, in the region and worldwide, of changes in opium poppy cultivation and opium production in Afghanistan. reireg
more
Constituting the fourth part of the World Drug Report 2022, this booklet focuses on the market dynamics of various stimulants – cocaine, amphetamines and “ecstasy” – and of NPS.
The first chapter contains an analysis of the global market for cocaine, starting with a review of cocaine supply..., including trends in the cultivation of coca bush and in the manufacture of and trafficking in cocaine at the global level and in the various regions. An analysis of different eradication strategies is included, as well as of the role of women in the cocaine supply chain. The chapter also presents the latest estimates of and trends in cocaine use, including a brief introduction to the various cocaine consumer products. Finally, it reviews the trends in the use of cocaine and the impact of the coronavirus disease (COVID-19) pandemic in different regions
more
The booklet starts with a general overview of how illicit drugs and the environment are linked within the bigger picture of the Sustainable Development Goals, climate change and environmental sustainability. It highlights direct and indirect linkages and gives examples of the significant local and i...ndividual-level impact that drugs can have on the environment. This is followed by a more in-depth overview of the latest scientific evidence for plant-based drugs and for synthetic drugs. For plant-based drugs, for example, this includes an analysis of the relationship between illicit crop cultivation and deforestation. For synthetic drugs, it includes an analysis of waste composition, volumes, and dumping and discharge, as well as the relation with wastewater treatment.
more
From choice, a world of possibilities
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
Open Journal of Epidemiology, 2018, 8, 226-241
Abstract
Introduction: Road traffic accidents (RTAs) are a major public health issue
in developing countries, where roads tend to be built haphazardly and accidents
take a heavy toll on victims—including leaving them disabled. This
study seeks ...to identify those factors that cause RTA victims to become disabled
as a result of their injuries. Methods: This retrospective community-
based study looked at RTA victims treated in five public and faith-based
hospitals in Benin. Disability was evaluated using the Washington Group on
Disabilities Statistics questionnaire. The independent variables were related to
the victim’s socio-demographic traits, the circumstances of the accident, and
post-crash response mechanisms. The proportions were compared using the
chi-squared test, with a threshold of 5%. Results: The prevalence of disability
among road traffic accident victims is 9.59% (CI 95%: 6.86% - 13.20%). The
occurrence of disability is associated with age (p = 0.002), occupational group
(p = 0.0077), the mode of transport used to transfer the victim (p < 0.001)
and the location of the injuries (p = 0.0035). The study also found that people
fail to make sufficient use of post-crash response mechanisms. Conclusion:
Public policy-makers should therefore focus on stepping up interventions to
get more people using both protective equipment and post-crash response services.
more
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
3rd Edition – July 2017
www.msfaccess.org
PLOS ONE | https://doi.org/10.1371/journal.pone.0192765 February 23, 2018